Citadel Advisors
CCCC icon

Citadel Advisors’s C4 Therapeutics CCCC Stock Holding History

Citadel Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6M Buy
4,187,580
+1,676,565
+67% +$5.73M ﹤0.01% 2622
2026
Q1 		$6.6M Buy
2,511,015
+2,063,207
+461% +$4.86M ﹤0.01% 3893
2025
Q4 		$855K Sell
447,808
-33,641
-7% -$79.7K ﹤0.01% 7751
2025
Q3 		$1.07M Buy
+481,449
New +$1.16M ﹤0.01% 7398
2025
Q1 		– Sell
-28,616
Closed -$103K – 14553
2024
Q4 		$103K Sell
28,616
-5,481
-16% -$27.3K ﹤0.01% 11442
2024
Q3 		$194K Sell
34,097
-339,560
-91% -$2.04M ﹤0.01% 10193
2024
Q2 		$1.73M Buy
373,657
+39,139
+12% +$233K ﹤0.01% 5589
2024
Q1 		$2.73M Buy
334,518
+287,304
+609% +$2.23M ﹤0.01% 4947
2023
Q4 		$267K Sell
47,214
-346,728
-88% -$791K ﹤0.01% 9392
2023
Q3 		$733K Sell
393,942
-275,540
-41% -$840K ﹤0.01% 7247
2023
Q2 		$1.84M Buy
669,482
+142,328
+27% +$457K ﹤0.01% 5291
2023
Q1 		$1.66M Buy
527,154
+147,654
+39% +$869K ﹤0.01% 5730
2022
Q4 		$2.24M Buy
379,500
+249,713
+192% +$2.07M ﹤0.01% 5265
2022
Q3 		$1.14M Buy
129,787
+101,836
+364% +$1.06M ﹤0.01% 6713
2022
Q2 		$211K Sell
27,951
-80,278
-74% -$706K ﹤0.01% 10589
2022
Q1 		$2.63M Sell
108,229
-53,727
-33% -$1.3M ﹤0.01% 5477
2021
Q4 		$5.21M Buy
161,956
+121,621
+302% +$4.81M ﹤0.01% 4216
2021
Q3 		$1.8M Sell
40,335
-70,443
-64% -$3.02M ﹤0.01% 6638
2021
Q2 		$4.19M Buy
110,778
+90,527
+447% +$3.24M ﹤0.01% 4824
2021
Q1 		$749K Sell
20,251
-83,622
-81% -$3.33M ﹤0.01% 8796
2020
Q4 		$3.44M Buy
+103,873
New +$3.01M ﹤0.01% 4349

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Citadel Advisors's CCCC Position: Q2 2026 in Review

Citadel Advisors increased its C4 Therapeutics (CCCC) stake by 67% in Q2 2026, buying an estimated $5.73M and bringing the position to 4,187,580 shares worth $19.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2622.

Citadel Advisors first reported a position in CCCC in Q4 2020 and has held it in 21 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Citadel Advisors held 4,187,580 shares of C4 Therapeutics worth $19.6M as of Q2 2026.
  • Citadel Advisors bought 1,676,565 C4 Therapeutics shares in Q2 2026, an estimated $5.73M.
  • C4 Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2622 holding.
  • Citadel Advisors first reported a position in C4 Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.